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Theobesity hormone leptin has been implicated in breast cancer development. Breast cancer cells express the leptin receptor and are able
to synthesize leptin in response to obesity-related stimuli. Furthermore, leptin is a positive regulator of vascular endothelial growth factor
(VEGF) and high levels of both proteins are associated with worse prognosis in breast cancer patients. Peroxisome proliferator-activated
receptor g (PPARg) ligands are therapeutic agents used in patient with Type 2 diabetes and obesity which have recently been studied for
their potential anti-tumor effect. Here, we studied if these compounds, ciglitazone and GW1929, can affect the expression of leptin and
VEGF in breast cancer cells. In MDA-MB-231 and MCF-7 breast cancer cells, treatment with submolar concentrations of ciglitazone and
GW1929 elevated the expression of leptin andVEGFmRNAandprotein, and increased cell viability andmigration. These effects coincided
with increased recruitment of PPARg to the proximal leptin promoter and decreased association of a transcriptional factor Sp1 with this
DNA region.
J. Cell. Physiol. 228: 1368–1374, 2013.  2012 Wiley Periodicals, Inc.
Leptin is a hormone produced mostly by the adipose tissue. In
addition to its well-documented role in the control of appetite
and energy homeostasis, leptin is known to regulate various
physiological and pathological processes in the peripheral
organs. The accumulating evidence suggests that leptin can
induce growth and progression of different cancer types, which
in part could explain the link between excess body adipocity and
increased cancer risk (Garofalo and Surmacz, 2006). In fact, data
obtained in cellular and animal cancer models demonstrated
that leptin can act as a mitogenic, motogenic, survival and
angiogenic factor (Surmacz, 2007; Anagnostoulis et al., 2008;
Ferla et al., 2011).
The importance of leptin signaling in breast cancer is
conﬁrmed by the fact that malignant breast tumors, but not
normalmammary epithelium, overexpress both leptin andObR
(Garofalo et al., 2006; Fiorio et al., 2008) and the leptin/ObR
system often correlates with higher tumor grade and worse
prognosis (Garofalo et al., 2006).
Themechanismof leptin expression in breast cancer cells has
been partially elucidated. We demonstrated that leptin can be
induced by hyperinsulinemia and hypoxia (Garofalo et al., 2006;
Koda et al., 2007; Cascio et al., 2008). On the molecular level,
these effects are mediated through interactions of Sp1 and/or
hypoxia-inducible factor-1 alpha (HIF-1a) with speciﬁc motifs
within the leptin gene promoter (Bartella et al., 2008; Cascio
et al., 2008). In addition, leptin expression in breast cancer cells
is likely to bemodulated by other transcription factors (Bartella
et al., 2008), for example, peroxisome proliferator-activated
receptor g (PPARg; Hollenberg et al., 1997).
The actions of leptin are mediated through the leptin
receptor (ObR). Binding of leptin to the long form of ObR
induces multiple pathways, including the Jak/STAT3, ERK1/2,
and PI-3K/Akt pathways. In addition, leptin induces cyclin D1
expression and retinoblastoma protein hyperphosphorylation
(Garofalo and Surmacz, 2006). Leptin also inﬂuences other
signaling systems, for example, it can transactivate the
epidermal growth factor receptor 1 (EGFR1), the human
epidermal growth factor receptor 2 (HER2), and the insulin-like
growth factor 1 receptor (IGF-IR; Shida et al., 2005; Fiorio
et al., 2008; Ozbay and Nahta, 2008). Furthermore, leptin can
induce the synthesis of ﬁbroblast growth factor 2 (FGF2) and
vascular endothelial growth factor (VEGF; Cao et al., 2001;
Garofalo and Surmacz, 2006; Surmacz, 2007). Inhibition of
leptin signaling suppresses the expression of VEGF/VEGFR2
and reduces the growth of mouse mammary tumors and
human breast cancer xenografts (Gonzalez et al., 2006;
Otvos et al., 2011).
VEGF promotes growth, proliferation, migration, formation
of new blood vessels (Bernatchez et al., 2002) and survival
of endothelial cells. VEGF regulation can occur at both
transcriptional and post-transcriptional levels in a cell-speciﬁc
manner (Claffey and Robinson, 1996). The proximal GC-rich
region in the VEGF promoter contains binding sites for AP2,
Erg-1, WT1, NFkB, and SP1/SP3 transcription factors, while
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distal enhancer sites bind HIF-1a (Shima et al., 1996; Gille et al.,
1997; Hanson et al., 2007). Inmousemammary tumor cells, 4T1
leptin upregulates VEGF expression through Sp1 (Gonzalez-
Perez et al., 2010).
PPARg are ligand-activated transcription factors, members
of the nuclear receptor superfamily. PPARg can be activated by
its natural ligand, the prostanoid 15-deoxy-prostaglandin J2, its
synthetic ligands, such as the N-aryl tyrosine derivative as
GW1929 as well as thiazolidinediones (TZDs), including
troglitazone, rosiglitazone, pioglitazone, and ciglitazone, a class
of drugs used to improve lipid and glucosemetabolism in Type 2
diabetes (Saltiel and Olefsky, 1996). In rats, treatment with
PPARg synthetic ligands reduced leptin mRNA levels in the
adipose tissue (Kallen and Lazar, 1996), and results obtained in
primary rat adipocytes demonstrated that the proximal leptin
promoter (65 toþ9) is negatively regulated by PPARg ligand.
In this case, PPARg does not bind directly any speciﬁc DNA
sequencewithin this region, but antagonizes the association of a
transcriptional leptin regulator, C/EBPa, at 65/þ9
(Hollenberg et al., 1997). In obese humans, 200mg troglitazone
administered twice daily does not affect fasting plasma leptin
concentrations (Nolan et al., 1996), and in Type 2 diabetic
patients, leptin levels do not change following treatment with
rosiglitazone (8mg/day) and pioglitazone (45mg/day; Miyazaki
and DeFronzo, 2008). In human cultured adipocytes, activation
of PPARg alone had little effect on leptin production, but
inhibited dexamethasone-induced leptin release (Williams
et al., 2000).
There is evidence that the expression of PPARg is increased
in several cancers, including breast, prostate, pancreas, and
colon (Koefﬂer, 2003; Kristiansen et al., 2006) and decreased in
others, such as esophagus and uterus (Terashita et al., 2002;
Jung et al., 2005). However, the role of PPARg in cancer
progression remains controversial. While some reports
demonstrated anti-proliferative role of PPARg ligands in
cellular and animal models of human cancer (Grommes et al.,
2004), other documented that activation of PPARg can induce
cell growth and tumor proliferation, depending on the dose and
duration of treatment (Clay et al., 2001; Fujita et al., 2003; Choi
et al., 2008; Talbert et al., 2008). Notably, PPARg agonists have
been shown to stimulate angiogenesis through upregulation of
VEGF and other yet unidentiﬁed pro-angiogenic factors
(Biscetti et al., 2008). Recently, the Food and Drug
Administration (FDA) announced that use of pioglitazone for
more than 1 year may be associated with an increased risk of
bladder cancer (Lewis et al., 2011). In this regard, several studies
in the last years seem to conﬁrm the correlation between the
use of TZDs and the risk of bladder cancer among people with
Type 2 diabetes (Colmers et al., 2012; Kermode-Scott, 2012;
Mamtani et al., 2012).
The role of PPARg in breast cancer is not clear. In vivo and
in vitro data demonstrate that PPARg ligands can suppress
breast cancer growth (Elstner et al., 1998; Suh et al., 1999).
However, experiments using transgenic mice suggest that
constitutive PPARg signaling has no effects on mammary
gland differentiation or function, but accelerates tumor
appearance and mortality in mammary cancer-prone mice
expressing the polyomamiddle T antigen (Saez et al., 2004). In
humans, troglitazone does not exhibit clinical response in
treatment-refractory metastatic breast cancer (Burstein
et al., 2003). Similarly, rosiglitazone has no effect on cell
proliferation and fasting serum leptin levels in a prospective
study evaluating therapy of early-stage breast cancer (Yee
et al., 2007).
In light of the ambiguous role of PPARg in cancer and
considering that high levels of leptin and VEGF are strongly
linked to worse prognosis of breast cancer, we investigated if
and how PPARg agonists can regulate leptin and VEGF
expression in breast cancer cells.
Materials and Methods
PPARg ligands
Ciglitazone (CGZ) and GW1929 (GW) were used to speciﬁcally
activate, while T0070907 (T0) to inhibit PPARg. All compounds
were purchased from Sigma–Aldrich (St. Louis, MO) and
solubilized in DMSO.
Cell culture
Human breast cancer cell lines MDA-MB-231 and MCF-7 were
purchased from the American Type Culture Collection (Rockville,
MD) and grown in Dulbecco’s modiﬁed Eagle’s medium
(DMEM:F12; Cellgro, Herndon, VA) containing 10% fetal bovine
serum (FBS) and 1% penicillin/streptomycin (Cellgro).
Cell growth assay
For cell growth assays, MDA-MB-231 and MCF-7 cells were plated
into 96-well plates, incubated at 378C in a humidiﬁed atmosphere
of 5% of CO2, allowed to attach overnight, transferred to SFM for
24 h and then stimulatedwith PPARg agonists alone (CGZorGW)
or in combinationwith the antagonist (T0) at concentrations of 0.5,
5, and 10mM/L for 24 h, or 0.05% dimethyl sulphoxide (DMSO; as
control). After 24 h, cell proliferationwas assessed by anMTTassay
performed according to manufacturer’s instructions (Millipore,
Temecula, CA).
Real-time quantitative PCR (QRT-PCR)
MDA-MB-231 and MCF-7 were synchronized in SFM for 24 h, and
then treated for 24 h with 0.5mMof CGZ or 0.5mMGW, alone or
in combination with 0.5mM T0.
Total cellular RNA was isolated using TRIzol reagent
(Invitrogen, Carlsbad, CA). Five microgram of total RNA was
reverse transcribed using the TaqMan RT kit (Applied Biosystems,
Branchburg, CA), according to vendor’s instructions. Five
microliters of the RT products were used to amplify leptin and
VEGF sequences using the Hs00174877 A1 Lep and the
Hs00900054_m1 VEGFA TaqMan probe (Applied Biosystems). To
normalize QRT-PCR reactions, parallel TaqMan b-actin control
reagents assays (Applied Biosystems) were run on each sample.
Changes in the leptin and VEGF mRNA content relative to b-actin
mRNA were determined using a comparative CT method (ABI
User Bulletin no. 2) to calculate changes in CT, and ultimately fold
and percent change. An average CT value for each RNA was
obtained for triplicate reactions.
ELISA
SubconﬂuentMDA-MB-231 andMCF-7 cell cultureswere placed in
SFM for 24 h, and then treated with 0.5mMof CGZ or 0.5mMGW
for 24 h, alone or in combination with 0.5mM T0. Conditioned
medium obtained from four plates treated cell cultures was
collected, centrifuged at 2,000 rpm for 5min, and the supernatants
frozen at 808C until use, to evaluate the concentration of leptin.
For the VEGF, instead, was used conditioned medium obtained
from a single plate.
The abundance of leptin and VEGF in cell conditioned medium
was measured using the VEGF ELISA (R&D Systems, Minneapolis,
MN) and ELISA low range leptin kit (Arcus Biologicals, Modena,
Italy) following manufacturer’s instructions.
Chromatin immunoprecipitation (ChIP)
Following treatment with 0.5mM of CGZ for 24 h, the cells were
crosslinked with 1% formaldehyde and chromatin was collected
and sonicated. Soluble chromatin was immunoprecipitated with
the following antibodies (Abs): PPARg (H-100) Ab (Santa Cruz
Biotechnology, Santa Cruz, CA), Sp1 PEP2 (Santa Cruz
Biotechnology). DNA–protein immune complexes were eluted,
reverse crosslinked, and DNA was extracted.
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Real-time quantitative PCR (QRT-PCR) analysis of ChIP DNA
fragments
QRT-PCR of DNAobtained fromChIPwas performed using SYBR
Green I (Applied Biosystems, Foster City, CA). The presence
of leptin proximal promoter DNA in PPARg and Sp1 ChIPs
was tested using the following primers from 488 to þ26:
forward 50-TCTAACCCTGGGCTTCCCT-30 and reverse
50-AACCGTTGGCGCTGCGATT-30. The PCR conditions were:
40 cycles at 1min, 30 sec at 958C, 30 sec at 588C, 1min at 728C. In
control samples, the primary Abs were replaced with appropriate
non-immune IgGs. To normalize QRT-PCR reactions, chromatin
inputs were used as control andwere run on each sample. Changes
in the content relative to input were determined using a
comparative CT method (ABI User Bulletin no. 2) to calculate
changes in CT, and ultimately fold and percent change. An average
CT value for each samples was obtained for triplicate reactions.
Western blotting (WB)
The expression of nuclear proteins was analyzed in 100mg of
nuclear cell lysates. TheAbswere used forWB: PPARg (H-100) Ab
(Santa Cruz), Sp1 (PEP2) Ab (Santa Cruz), and nucleolin Ab (Santa
Cruz).
Matrigel invasion assay
The invasive potential of MDA-MB-231 and MCF-7 breast cancer
cells after treatment for 24 h with 0.5mMCGZ was assessed using
BioCoat invasion chambers (24-well companion plates with cell
culture inserts containing 8-mm pore size ﬁlters coated with
matrigel; Becton Dickinson Biosciences, Franklin Lakes, NJ),
following manufacturer’s instructions. 5 104 MDA-MB-231 and
MCF-7 cells treated with DMSO or 0.5mM/L of CGZ were
suspended in 500ml of DMEM and plated in upper chambers of
inserts, while the chemoattractant (50% FBS) was placed in lower
chambers. The chamberswere incubated for 24 h at 378C, 5%CO2.
After that, the non-invading cells were removed from the upper
surface of the ﬁlter with a cotton-tipped applicator, while the cells
that migrated through the pores and attached to the undersurface
of the ﬁlter were ﬁxed and stained. Themembranesweremounted
on glass slides, and the number of cells in ﬁve random microscopic
ﬁelds (20magniﬁcation)was scored for each experimental group.
All experiments were run in triplicate, and invasiveness was
calculated as the percentage invasion through the matrigel relative
to the migration through the control membrane, as described in
the manufacturer’s instructions.
Results
Effects of PPARg ligands on breast cancer cells viability
Considering the differential activity of PPARg in cancer cells
depending on doses applied and duration of treatment (Clay
et al., 2001; Fujita et al., 2003; Choi et al., 2008; Talbert et al.,
2008), we ﬁrst tested the effects of different concentrations
(0.5, 5, and 10mM) of CGZ and GW on viability of MDA-MB-
231 and MCF-7 breast cancer cells at 24 h. Each treatment was
used alone or in combination with the antagonist T0 (Fig. 1 and
Table 1).
The results ofMTT assays suggested that in both cell lines the
activation of PPARg by lower concentrations (0.5 and 5mM) of
CGZ and GW increase cell viability relative to DMSO-treated
controls. At higher concentrations (10mM) CGZ and GW did
not induce any signiﬁcant change in cell viability versus control
(Fig. 1; Table 1).
In parallel experiments, CGZ and GW were tested in
combination with T0, a PPARg antagonist. In both cell lines, T0
reduced the effects of agonists especially for concentrations 0.5
and 5mM (Fig. 1; Table 1).
Effects of submolar concentrations of PPARg agonists on
leptin expression
In order to determine whether low concentrations of PPARg
agonists can inﬂuence leptin expression MDA-MB-231 and
MCF-7, breast cancer cells were treated for 24 hwith 0.5mMof
CGZ and GW in the presence or absence of the antagonist T0.
Q-RT-PCR showed that submolar concentration of agonists
stimulates the expression of leptin mRNA compared to control
(DMSO). In detail, after treatment with 0.5mM of CGZ, leptin
mRNA increases of 2-fold in MDA-MB-231 and of 1.2-fold
in MCF-7. Similar increment was observed with GW (1.6-fold
in MDA-MB-231 and 1.4-fold in MCF-7; Fig. 2a).
Next experiments using a speciﬁc leptin ELISA assay
demonstrated 0.5mM CGZ or 0.5mM GW stimulates the
secretion of leptin to conditioned medium in MDA-MB-231
(1.4-foldwithCGZand1.2-foldwithGWvs.DMSO); inMCF-7,
CGZ does not induce any change while GW induces an
increment of 1.2-fold versus DMSO (Fig. 2b). In addition, the
Fig. 1. Effects of different doses of PPARg ligands onbreast cancer cells growth.MTTanalysis forMDA-MB-231 andMCF-7 cells stimulatedwith
PPARgagonistsalone(CGZorGW)or incombinationwiththeantagonist (T0)atconcentrationsof0.5,5,and10mMfor24 h,comparetodimethyl
sulphoxide (DMSO) as described in Materials and Methods Section. Data, representative of three different experiments each performed in
triplicate, are presented as fold changeWof cell viability relative to the control (P £0.05).
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combined treatment with the antagonist blocked the effects of
the agonists both for mRNA and proteins levels (Fig. 2a,b).
Submolar concentrations of CGZ increase the
association of PPARg and reduce the binding of Sp1 with
the proximal leptin promoter
Sp1 is a transcription factor able to interact with speciﬁc motifs
within the leptin gene promoter under certain stimuli (Bartella
et al., 2008).
Using ChIP assays we investigated the effects of CGZ on the
binding of PPARg and Sp1 to the proximal leptin promoter
region (from 488 to þ26). Contrary to earlier ﬁndings in rat
adipocytes (Hollenberg et al., 1997), we found that inMDA-MB-
231 and MCF-7 breast cancer cells, PPARg directly binds this
region. Speciﬁcally, the treatment with 0.5mM CGZ for 24 h
increased PPARg loading on this DNA region by 2.1-fold in
MDA-MB-231 and by 2.5-fold in MCF-7 cells. In parallel, CGZ
treatment reduced Sp1 binding to this DNA region by 0.7-fold
in MDA-MB-231 and by 0.3-fold in MCF-7 cells (Fig. 3a).
Chromatin samples precipitated with control antibodies did
not reveal any Q-RT-PCR products (data not shown).
The differential association of PPARg and Sp1 with the
proximal leptin promoter was not related to differences in
the nuclear abundance of these factors in response to CGZ
treatment. In fact, we only noticed a 20% reduction of PPARg
and a 10% increment of Sp1 nuclear levels after 24 h of CGZ
treatment in MDA-MB-231 cells. In MCF-7 cells, the levels of
both factors remained unchanged (Fig. 3b).
Effects of submolar concentrations of PPARg agonists on
VEGF expression
Since leptin is able to increase VEGF expression (Gonzalez-
Perez et al., 2010) and PPARg might regulate VEGF
transcription (Biscetti et al., 2008), we assessed VEGF mRNA
levels following the treatment with 0.5mM of CGZ and GW in
MCF-7 and MDA-MB-231 cells (Fig. 4a). We found that the
agonists activated VEGF expression in MDA-MB-231 cells by
1.5-foldwithCGZ and 1.2-foldwithGW, but not inMCF-7 cells
(Fig. 4a).
Interestingly, using speciﬁc ELISA assays, we found that
0.5mM of CGZ or GW stimulated the secretion of VEGF in
both cell lines (Fig. 4b). Speciﬁcally, VEGF secretion increased
1.8-fold with CGZ and 1.5-fold with GW in MDA-MB-231,
while inMCF-7 a 1.2- and 1.6-fold increasewas notedwithCGZ
and GW versus DMSO, respectively (Fig. 4b). In addition, the
combined treatment with the antagonist blocked the effects of
the agonists both for mRNA and proteins levels (Fig. 4a,b).
Effects of submolar concentrations of CGZ on the
invasion of MDA-MB-231 and MCF-7 breast cancer cells
Leptin and VEGF are known motogenic factors for breast
cancer cells (Bernatchez et al., 2002; Surmacz, 2007). Since both
these proteins were induced by PPARg agonists, we assayed
whether submolar concentration of CGZ can induce invasive
capacities of MDA-MB-231 and MCF-7 breast cancer cells
(Fig. 5a).We found that relative to controls, the treatment with
Fig. 2. Effects of submolar doses of CGZ and GW on leptin
production. a: The abundance of leptin mRNA was studied using
QRT-PCR in MDA-MB-231 and MCF-7 cells treated with 0.5mM of
CGZ/GW, alone or in combination with T0, for 24 h, relative to cells
treated with DMSO as described in Materials and Methods Section.
The graphs represent the increase of leptin mRNA relative to the
increase of constitutive mRNA control (b-actin) in the same
sampleWSD. b: With ELISA assay, the abundance of secreted leptin
(pg/ml) was analyzed in conditioned medium of cells treated with
0.5mMofCGZ/GW, alone or in combinationwithT0, for 24 h, relative
to cells treated with DMSO as described in Materials and Methods
Section.Thedifferences between the three conditions (CGZ/GW/T0)
and DMSO were statistically signiﬁcant (P< 0.05).
TABLE 1. Effects of PPARg ligands (CGZ and GW) on breast cancer cell viability
MDA-MB-231 MCF-7
0.5mM 5mM 10mM 0.5mM 5mM 10mM
CGZ 2.3 0.052 1.7 0.044 1 0.054 3.1 0.048 2.5 0.053 1.2 0.05
CGZþT0 1.6 0.051 0.9 0.057 0.8 0.049 1.7 0.044 1.3 0.056 1.2 0.047
GW 2.5 0.050 2.4 0.048 1.3 0.046 1.5 0.042 2.7 0.052 1.5 0.046
GWþT0 1.1 0.045 1 0.055 0.8 0.045 1.2 0.052 1.2 0.054 1.1 0.043
Data, representative of three different experiments each performed in triplicate, are presented as fold change of cell viability relative to the control, P 0.05.
DMSO values are taken as¼ 1, and treatment values represent fold increase relative to DMSO.
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0.5mM CGZ for 24 h increased the number of invading MDA-
MB-231 and MCF-7 cells by 1.9- and 3.2-fold respectively
(Fig. 5b).
Discussion
The role of PPARg agonists in cancer is unclear. The evidence
from preclinical and clinical studies suggests that some PPARy
agonists might promote cancer development. For instance,
Piccinni et al. (2011) reported an association between the use of
pioglitazone and the onset of bladder cancer, while Lewis et al.
(2011) noted that only long-term (over 2 years), but not short-
term, use of pioglitazone was weakly associated with increased
risk for this disease. In addition, several studies employing in
vitro and in vivo models indicated that PPARy agonists might
be involved in breast and colon cancer (Clay et al., 2001;
Fujita et al., 2003; Saez et al., 2004; Choi et al., 2008; Talbert
et al., 2008).
Here, we studied the effects of CGZ and GW on the
expression of two oncogenic proteins, leptin and VEGF in
cellular models of breast cancer. We found that submolar
concentrations of CGZ and GW increased leptin mRNA and
protein levels in both studied cell lines (Fig. 2). These results are
in contrast to what was observed in rat adipocytes where
thiazolidinediones at doses ranged between 5 and 500 nM
downregulated leptin gene expression (Kallen and Lazar, 1996).
These differences could be attributed to different cell context
or different PPARg-speciﬁc ligands (CGZ and GW vs.
BRL49653). In humans, PPARg agonists (e.g., thiazolidinediones
pioglitazone and rosiglitazone) are administered at low-
medium mg/day doses, which correspond to sub- to med-M
concentrations in vitro. While, some authors demonstrated
that such doses had no effect on breast cancer cell proliferation
and circulating fasting plasma leptin concentrations
(Nolan et al., 1996; Yee et al., 2007), their effects on intraorgan
leptin levels were never assessed and remain unknown.
Fig. 4. Effects of submolar doses of CGZ and GW on VEGF
production. a: The abundance of VEGF mRNA was studied using
QRT-PCR in MCF-7 and MDA-MB-231 cells treated with 0.5mM of
CGZ/GW, alone or in combination with T0, for 24 h, relative to cells
treated with DMSO as described in Materials and Methods Section.
The graphs represent the increase of VEGF mRNA relative to the
increase of constitutive mRNA control (b-actin) in the same
sampleWSD. b: With ELISA assay, the abundance of secreted VEGF
(pg/ml) was analyzed in conditioned medium of cells treated with
0.5mMofCGZ/GW, alone or in combinationwithT0, for 24 h, relative
to cells treated with DMSO as described in Materials and Methods
Section. The differences between the two conditions (CGZ/GW/TO
and DMSO) were statistically signiﬁcant (P<0.05).
Fig. 3. Submolar CGZ increases the association of PPARg and
reduces the binding of Sp1 with the proximal leptin promoter. a: The
binding of PPARg and Sp1 to the proximal leptin promoter region
(488/R26) was tested by ChIP and QRT-PCR in MDA-MB-231 and
MCF-7 cells treated with 0.5mM of CGZ or DMSO for 24 h, as
described in Materials and Methods Section. b: The expression of
nuclear Sp1 and PPARg was analyzed by WB in 100mg of nuclear
proteins obtained fromcells treatedwith 0.5mMofCGZorDMSO for
24 h, as described in Materials and Methods Section. Protein loading
was controlled by re-probing the WB ﬁlter for the expression of a
nuclear marker nucleolin (NUC).
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In our study, the CGZ-dependent upregulation of leptin
mRNA and protein levels coincided with increased association
of PPARg to the proximal leptin promoter (488 toþ26) and
reduced binding of Sp1 to this DNA region (Fig. 3a). The
differential association of PPARg and Sp1 with the proximal
leptin promoter was not related to differences in the nuclear
abundance of these factors in response to CGZ treatment
(Fig. 3b). We speculate that PPARy and Sp1 binding sites in the
leptin promoter are overlapping, and the treatment with TZD
could result in displacement of basal Sp1 levels. Our
observations are at variance with the results obtained in
primary rat adipocytes, where the leptin promoter region at
65/þ9 was negatively regulated by PPARg ligands via a
mechanism not involving direct PPARg binding to DNA
(Hollenberg et al., 1997).
We also demonstrated that 0.5mM of agonists increased
VEGF mRNA only in MDA-MB-231. In MCF-7, PPARg agonists
did not alter VEGF mRNA levels but modulated protein levels
through yet unclear mechanisms (Fig. 4).
We speculate that higher levels of leptin and VEGF can, at
least in part, explain observed increased in viability (Fig. 1) and
migration (Fig. 5) of MDA-MB-231 and MCF-7 cells under
0.5mM of CGZ treatment.
In general, our results are consistent with the ﬁnding that
PPARg agonists can stimulate angiogenesis through
upregulation of VEGF and other yet unidentiﬁed pro-angiogenic
factors (Biscetti et al., 2008) and leptin could be one of these
factors, stimulating angiogenesis independently (Anagnostoulis
et al., 2008) or through enhanced expression of VEGF (Cao
et al., 2001).
In summary, our study, for the ﬁrst time, provided evidence
that submolar concentrations of PPARg agonists may induce
survival and migration of MDA-MB-231 and MCF-7 breast
cancer cells probably through up-regulation of leptin and VEGF,
both factors implicated in tumor growth and progression.
Together with previous reports on proliferative and
angiogenic effects of PPARg agonists observed with low doses
of these compounds (Clay et al., 2001) and considering recent
data emerging from clinical studies (Lewis et al., 2011; Piccinni
et al., 2011; Colmers et al., 2012; Kermode-Scott, 2012;
Mamtani et al., 2012) our results add to the debate about
relative risk-beneﬁt proﬁle of PPARg targeting drugs.
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